141 related articles for article (PubMed ID: 32619468)
1. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2020 Jul; 79(1):191-198.e3. PubMed ID: 32619469
[TBL] [Abstract][Full Text] [Related]
3. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2017 Oct; 68(1):210-223.e6. PubMed ID: 28985505
[TBL] [Abstract][Full Text] [Related]
4. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.
Lu T; Laughton CA; Wang S; Bradshaw TD
Mol Pharmacol; 2015 Jan; 87(1):18-30. PubMed ID: 25316768
[TBL] [Abstract][Full Text] [Related]
6. Blockade of RAS-Binding Domain Interactions Inhibits RAS Signaling.
Cancer Discov; 2016 Jun; 6(6):573. PubMed ID: 27150538
[TBL] [Abstract][Full Text] [Related]
7. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
8. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
9. [Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].
Xu F; Chang CK; Li X; He Q; Wu LY; Zhang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1362-1366. PubMed ID: 29070108
[TBL] [Abstract][Full Text] [Related]
10. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Malacrida A; Rigolio R; Celio L; Damian S; Cavaletti G; Mazzaferro V; Miloso M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360994
[TBL] [Abstract][Full Text] [Related]
13. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Athuluri-Divakar SK; Vasquez-Del Carpio R; Dutta K; Baker SJ; Cosenza SC; Basu I; Gupta YK; Reddy MV; Ueno L; Hart JR; Vogt PK; Mulholland D; Guha C; Aggarwal AK; Reddy EP
Cell; 2016 Apr; 165(3):643-55. PubMed ID: 27104980
[TBL] [Abstract][Full Text] [Related]
14. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
16. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A; de Cárcer G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
[TBL] [Abstract][Full Text] [Related]
17. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
18. Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.
Pallela VR; Mallireddigari MR; Cosenza SC; Akula B; Subbaiah DR; Reddy EP; Reddy MV
Org Biomol Chem; 2013 Mar; 11(12):1964-77. PubMed ID: 23386308
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
20. Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair.
Malacrida A; Cavaletti G; Miloso M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
